Rune’s lead product is a novel anti-psychotic product for the treatment of early onset Schizophrenia.

Final formulation upscaling work is underway and will be completed within the next six months allowing the major Efficacy/Safety study work to be initiated early 2026.

Recruitment is always difficult for products treating rare diseases however we have an excellent relationship with a specialist Clinical Research Organisation to help take the product through its final stages as quickly as possible.